[The State Food and Drug Administration held a "Artificial Intelligence + Drug Supervision" work promotion meeting] On October 20, the State Food and Drug Administration held a "Artificial Intelligence + Drug Supervision" work promotion meeting. The meeting pointed out that artificial intelligence is a key variable affecting future development. It is deeply penetrating the entire chain of drug research and development, production, circulation and use, profoundly changing the industrial form and risk structure. The meeting emphasized that it is necessary to base on regulatory responsibilities, establish rules, stabilize expectations, strengthen services, cultivate the ecosystem, and actively promote the innovative development of the artificial intelligence-empowered pharmaceutical industry. It is necessary to formulate special plans to support key tracks to take the lead in breakthroughs, move review services to the source of innovation, and create a regulatory environment that encourages innovation, is inclusive and prudent. It is necessary to use artificial intelligence to improve the level of drug safety governance, promote smarter review and approval, more precise inspection and enforcement, more sensitive risk prevention and control, and more efficient coordinated supervision. It is necessary to consolidate basic guarantees, establish an artificial intelligence application management mechanism that covers the entire cycle and continue to iterate, strengthen resource coordination, cultivate a team of professional talents, promote "technology for good", and maintain the bottom line of artificial intelligence safety.